Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | BPTF | Q12830 | 1/20 | 0.42 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | F12 | P00748 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252826 | 0.88 | NOTUM (0.61) | NOTUMPTAFRBAZ2BMAPTLMNA | |
| SCHEMBL16111044 | 0.86 | AKR1C3 (0.51) | NOTUMAKR1C3MAPTLMNAABHD6 | |
| SCHEMBL3167899 | 0.84 | RIPK1 (0.57) | NOTUMAKR1C3ABHD6MEN1KMT2A | |
| SCHEMBL6712189 | 0.83 | NOTUM (0.63) | NOTUMAKR1C3PTAFRBAZ2BMAPT | |
| SCHEMBL10210758 | 0.83 | NOTUM (0.63) | NOTUMPTAFRBAZ2BMAPTLMNA | |
| SCHEMBL4008584 | 0.81 | NOTUM (0.61) | NOTUMAKR1C3PTAFRBAZ2BMAPT | |
| SCHEMBL4512420 | 0.81 | NOTUM (0.61) | NOTUMAKR1C3PTAFRMAPTLMNA | |
| SCHEMBL394214 | 0.80 | NR1H2 (0.60) | MAPTABHD6F12 | |
| SCHEMBL29526229 | 0.80 | NR1H2 (0.60) | MAPTABHD6F12 | |
| SCHEMBL16891568 | 0.80 | NOTUM (0.59) | NOTUMPTAFRBAZ2BMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2019-05-28 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| WO-2015158310-A1 | TYROSINE KINASE INHIBITOR AND USES THEREOF | 山东轩竹医药科技有限公司 | 2015-10-22 | — | — | WO | disclosed |
| EP-0266949-B1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4812573-A | ARYLSULFONAMIDE SUBSTITUTED TETRAHYDROISOQUINOLINYLALKANOIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITHKLINE & FRENCH LABORATORIES, LTD. (GB) | 1989-03-14 | — | — | US | disclosed |
| EP-0266949-A1 | Tetrahydroisoquinolin-2-yl derivatives of carboxylic acids as thromboxane A2 antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988003137-A1 | TETRAHYDROISOQUINOLIN-2-YL DERIVATIVES OF CARBOXYLIC ACIDS AS THROMBOXANE A2 ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | NOTUM 652/4885AKR1C3 3643/4885PTAFR 517/4885 |
| US-10300058-B2 | Tyrosine kinase inhibitor and uses thereof | EGFR, ERBB2, ABL1 | NOTUM 652/4885AKR1C3 3643/4885PTAFR 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.